Elecsys Total-Tau CSF

From the manufacturer

Quoted verbatim from the manufacturer’s published product page. IVDmap did not write or verify this text.

• The Elecsys Total-Tau CSF assay is not intended to be used as a stand-alone test and should only be used with the Elecsys β-Amyloid (1-42) CSF assay to calculate the ratio of Total-Tau (tTau) to β-Amyloid (1-42) (Abeta42) in CSF (tTau/Abeta42 ratio).

  Roche DiagnosticsProduct TypeManufacturer Page2026-10-16

• Intended useElecsys β‑Amyloid (1‑42) CSF II and Elecsys Total‑Tau CSF are in vitro electrochemiluminescence immunoassays for the measurement of the β‑Amyloid (1‑42) (Abeta42) and Total‑Tau (tTau) protein concentration in cerebrospinal fluid (CSF) from adult patients aged 55 years and older being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment to generate a…

  Roche DiagnosticsTechnology PlatformManufacturer Page2026-10-16

• The safety and effectiveness of the Elecsys Total‑Tau CSF assay have not been established for monitoring responses to therapies.The electrochemiluminescence immunoassay “ECLIA” is intended for use on

  Roche DiagnosticsCategory L1Manufacturer Page2026-10-06